Home / GU oncology / RCC / Metastatic RCC

RCC → Metastatic RCC

Last reviewed: 2026-09-22 · Next review: 2026-12-21

clinic-ready — 1L IO/IO vs IO/TKI by IMDC; no head-to-head among doublets in this pack

Who this applies to

Metastatic RCC; record histology (clear vs non-clear), sarcomatoid, IMDC risk (KPS, time from diagnosis to systemic therapy, hemoglobin, calcium, neutrophils, platelets), prior nephrectomy, prior adjuvant PD-1⁶⁷.

Standard options

Clinical context	Option	Key inclusion	Typical course
IMDC intermediate/poor risk, durability/complete-response priority	Nivolumab plus ipilimumab¹	Clear-cell advanced RCC and immune-therapy candidacy¹.	Induction followed by nivolumab maintenance in CheckMate 214¹.
Any IMDC risk with need for response and an acceptable TKI partner	PD-1/VEGFR combination²³⁴	Balance disease burden, organ function, hypertension, and toxicity profile⁶⁷.	Regimen-specific continuous TKI plus PD-1 schedule²³⁴.
After ICI and antiangiogenic therapy	Belzutifan or other sequence matched to prior exposure⁵	LITESPARK-005 population and local label⁵.	Regimen-specific⁵.
Non-clear-cell or atypical clinical context	Trial or individualized systemic approach⁶⁷	Do not apply clear-cell trial effect estimates unchanged⁶⁷.	Individualized⁶.

IMDC intermediate/poor, goal durability / CR: nivo 3 mg/kg + ipi 1 mg/kg q3wk ×4 then nivo (CheckMate 214)¹. Higher-grade irAE than TKI monotherapy; lower grade 3–4 TRAE than sunitinib in the primary paper¹.
Any IMDC, need response / TKI partner acceptable: pembro + axitinib (KEYNOTE-426)², nivo + cabo 40 mg (CheckMate 9ER)³, or pembro + lenvatinib 20 mg (CLEAR)⁴. Hypertension, diarrhea, hand-foot, hepatic toxicity²³⁴.
Do not add cabo to nivo/ipi as default (COSMIC-313: no OS gain, more grade 3/4 TRAE)⁶⁷.
Later line after VEGFR and ICI: belzutifan vs everolimus (LITESPARK-005) improved PFS/ORR not OS⁵. Nivo vs everolimus (CheckMate 025) is historical post-VEGFR⁶. TiNivo-2: adding nivo to tivozanib after ICI did not improve PFS⁶⁷.
Local therapy (CN, MDT) is individualized — not covered by these systemic trials⁶⁷.

Therapy sequencing

Starting point or prior exposure	Next treatment order	Branch point / evidence boundary
Untreated IMDC intermediate/poor-risk ccRCC, priority on durable response	Nivolumab plus ipilimumab induction → nivolumab maintenance¹.	This is an IO/IO pathway; it is not a direct comparison with each PD-1/VEGFR doublet¹⁶.
Untreated ccRCC, need for response or acceptable VEGFR partner	Start pembrolizumab/axitinib, nivolumab/cabozantinib, or pembrolizumab/lenvatinib²³⁴.	Select for disease burden, hypertension/proteinuria, liver function, and immune risk; no head-to-head doublet trial in this page identifies a universal preferred regimen⁶⁷.
Progression after both PD-1/PD-L1 and antiangiogenic therapy	Belzutifan⁵.	LITESPARK-005 directly studied this exposure sequence; its OS endpoint was not statistically significant at the reported analysis⁵.
Progression after IO/IO without prior VEGFR therapy	Choose a VEGFR-containing option before positioning belzutifan⁵⁶.	Belzutifan's direct pivotal population had prior ICI and antiangiogenic treatment; this page does not establish a single preferred post-IO/IO sequence⁵⁶.
Considering nivolumab/ipilimumab/cabozantinib	Do not add cabozantinib to IO/IO as default⁶⁷.	COSMIC-313 improved PFS but not OS and increased grade 3/4 treatment-related AEs⁶⁷.

Surveillance and treatment de-escalation

Response-assessment imaging schedule

Phase	Imaging cadence	Stop, hold, or de-escalate	Re-escalation / next line
Active first-line IO ± TKI (response assessment)⁶⁷	Cross-sectional imaging every 8–12 weeks while assessing response; CBC, CMP, TSH, blood pressure, urine protein; immune and TKI toxicity review each cycle⁶⁷.	Continue until progression or toxicity; nivo/ipi induction completes 4 cycles then nivo maintenance; TKI partners continue with PD-1 until progression unless toxicity mandates switch¹²³⁴. Hold TKI for hypertension, hand-foot, or hepatic toxicity; hold IO for immune events²³⁴.	Progression after ICI and VEGFR → belzutifan (LITESPARK-005 population) or trial; avoid default nivo/ipi/cabo (COSMIC-313 no OS gain)⁵⁶.
Prolonged response / durable disease control⁶⁷	After prolonged response, extend imaging intervals beyond 8–12 weeks when clinically appropriate per EAU/NCCN follow-up frameworks⁶⁷.	Treatment breaks are not trial-established for IO/TKI doublets; individualize only with shared decision⁶⁷.	Confirmed progression → next-line sequencing⁵⁶.

Cytoreductive nephrectomy and metastasis-directed therapy are individualized and not governed by these trial surveillance schedules⁶⁷.

Landmark evidence

Trial	Population	Intervention arm	Control arm	Key outcomes (both arms)	Key HR	Evidence status
CheckMate 214 NCT02231749	Untreated cc aRCC; N=1096; int/poor n=425 vs 422¹	Nivo 3 mg/kg + ipi 1 mg/kg q3wk ×4 → nivo¹	Sunitinib 50 mg 4 wk on / 2 wk off¹	Int/poor: 18-mo OS 75% vs 60%; median OS NR vs 26.0 mo; ORR 42% vs 27%; CR 9% vs 1%; PFS 11.6 vs 8.4 mo. 9.3-y ITT OS 31.4% vs 19.5% at 108 mo¹	Int/poor OS HR 0.63 (primary); 9.3-y ITT OS HR 0.71 (0.62–0.82); favorable OS HR 0.80 (0.59–1.09)¹	Motzer 2018 NEJM PMID 29562145¹
KEYNOTE-426 NCT02853331	Untreated cc aRCC; N=861²	Pembro 200 mg q3wk + axitinib 5 mg BID²	Sunitinib 50 mg 4/2²	12-mo OS 89.9% vs 78.3%; PFS 15.1 vs 11.1 mo; ORR 59.3% vs 35.7%. ≥5 y ORR 60.6% vs 39.6%²	OS HR 0.53 (0.38–0.74) interim; ≥5 y OS HR 0.84 (0.71–0.99); PFS HR 0.69 (0.59–0.81)²	Rini 2019 NEJM PMID 30779529²
CheckMate 9ER	Untreated cc aRCC; N=651³	Nivo 240 mg q2wk + cabo 40 mg daily³	Sunitinib 50 mg 4/2³	PFS 16.6 vs 8.3 mo; 12-mo OS 85.7% vs 75.6%; ORR 55.7% vs 27.1%; grade ≥3 AE 75.3% vs 70.6%³	PFS HR 0.51 (0.41–0.64); OS HR 0.60 (98.89% CI 0.40–0.89)³	Choueiri 2021 NEJM PMID 33657295³
CLEAR	Untreated aRCC; N=1069 (3-arm)⁴	Lenvatinib 20 mg daily + pembro 200 mg q3wk⁴	Sunitinib 50 mg 4/2 (also lenvatinib 18 mg + everolimus arm)⁴	PFS 23.9 vs 9.2 mo; grade ≥3 AE 82.4% vs 71.8%. Lenvatinib+everolimus OS not improved⁴	PFS HR 0.39 (0.32–0.49); OS HR 0.66 (0.49–0.88) vs sunitinib⁴	Motzer 2021 NEJM PMID 33616314⁴
COSMIC-313	Untreated IMDC int/poor ccRCC; N=855⁶	Cabo 40 mg + nivo + ipi⁶	Placebo + nivo + ipi⁶	Primary 12-mo PFS 57% vs 49%; final PFS 16.6 vs 11.2 mo; grade 3/4 TRAE 75% vs 43% at final⁶	Primary PFS HR 0.73 (0.57–0.94); final PFS HR 0.82 (0.69–0.98); OS HR 1.02 (0.85–1.23)⁶	Choueiri 2023 NEJM; final Ann Oncol — landscape row; practice point per guideline⁶⁷
LITESPARK-005	ccRCC after ICI + antiangiogenic; N=746⁵	Belzutifan 120 mg daily⁵	Everolimus 10 mg daily⁵	Median PFS 5.6 vs 5.6 mo; 18-mo PFS 24.0% vs 8.3%; ORR 21.9% vs 3.5%; OS 21.4 vs 18.1 mo⁵	OS HR 0.88 (0.73–1.07), NS⁵	FDA Welireg label / LITESPARK-005 labeled population⁵
CheckMate 025 NCT01668784	ccRCC after 1–2 antiangiogenic; N=821⁶	Nivo 3 mg/kg q2wk⁶	Everolimus 10 mg daily⁶	OS 25.0 vs 19.6 mo; ORR 25% vs 5%; PFS 4.6 vs 4.4 mo⁶	OS HR 0.73 (98.5% CI 0.57–0.93); PFS HR 0.88 (0.75–1.03) NS⁶	Historical post-VEGFR pathway per guideline framing⁶⁷
TiNivo-2 NCT04987203	aRCC after 1–2 lines including ICI; N=343⁶	Tivozanib 0.89 mg + nivo 480 mg q4wk⁶	Tivozanib 1.34 mg⁶	PFS 5.7 vs 7.4 mo⁶	PFS HR 1.10 (0.84–1.43)⁶	Later-line IO rechallenge not supported as default⁶⁷

KEYNOTE-564 adjuvant (watch): pembro ×1 y vs placebo after nephrectomy; 5-y OS 87.7% vs 82.3%; OS HR 0.66 (0.48–0.90)⁶⁷. Prior adjuvant PD-1 exposure informs metastatic sequencing⁶.

Biomarkers

Marker	Current clinic role	Emerging / investigational	How it changes decision now	Limits
Histology (clear-cell vs non-clear)	Primary frame for applying 1L doublet evidence⁶⁷	Non-clear-cell randomized first-line landscape still thinner than clear-cell⁶⁷	Clear-cell: use IO/IO or IO/VEGFR doublets as on this page; non-clear: trial or individualized approach without transplanting clear-cell effect sizes⁶⁷.	Sarcomatoid features may favor IO-containing regimens but do not replace IMDC/histology counseling⁶⁷.
IMDC risk	Practical 1L selector (especially for nivo/ipi intermediate/poor)¹⁶⁷	—	Intermediate/poor: durability/CR discussion often favors nivo/ipi; any-risk response need may favor PD-1/VEGFR¹²³⁴.	Does not rank IO/VEGFR doublets head-to-head⁶⁷.
PD-L1	Not the primary selector for these doublets¹²	Exploratory correlatives in 1L ICI trials¹²	Does not choose among approved doublets in routine clinic¹².	No validated threshold for regimen selection on this page¹².
Angiogenesis / T-cell expression signatures	Not used for routine regimen choice²	KEYNOTE-426 exploratory: TcellinfGEP and angiogenesis signatures associated with outcomes²	Does not change first-line doublet selection today².	Exploratory analyses only; no practice-ready cutoffs on this page².
Germline (VHL, FH, etc.)	Consider for non-clear histology or hereditary-syndrome features⁶⁹	Broader hereditary panels when indicated⁶⁹	Informs genetic counseling and selected targeted pathways; not required to start 1L IO doublets in sporadic ccRCC⁶⁹.	Does not replace IMDC or histology for 1L IO selection⁶⁷.

Upcoming research

Field direction: first-line IO doublets remain the core; HIF-2 (belzutifan) is moving earlier and into combinations, adjuvant pembrolizumab exposure changes relapse counseling, and non-clear-cell randomized first-line data remain thinner than clear-cell⁵⁶⁷.

Program or theme	Why it may change care	Evidence status
Relapse after adjuvant pembrolizumab (KEYNOTE-564)	Changes subsequent IO/VEGFR and trial eligibility counseling⁶⁷.	Adjuvant SOC established; relapse-path sequencing still evolving in practice⁶⁷.
Earlier / combination HIF-2 (belzutifan)	Could move HIF-2 ahead of current later-line use⁵⁶.	Later-line peer-reviewed/label evidence; earlier combinations not a 1L default in this pack⁵⁶.
Non-clear-cell randomized first-line landscape	Would define histology-specific doublets⁶⁷.	Not retrieved as a dedicated landscape on this page⁶⁷.
COSMIC-313 triplet	Triplet did not improve OS versus doublet in retrieved sources⁶⁷.	Negative OS for the triplet; not a care-changing upgrade⁶⁷.

Toxicity

Regimen and comparator	Trial-level safety outcomes	Counseling focus
Nivolumab plus ipilimumab versus sunitinib, CheckMate 214	Discontinuation for treatment-related AEs 22% vs 12%¹.	Promptly report diarrhea, abdominal pain, cough/dyspnea, rash, jaundice, fatigue, or endocrine symptoms; immune effects can persist¹.
Nivolumab plus cabozantinib versus sunitinib, CheckMate 9ER	Grade ≥3 AEs 75.3% vs 70.6%³.	Review hypertension, diarrhea, hand-foot/skin changes, hepatic symptoms, proteinuria, and immune toxicity³.
Lenvatinib plus pembrolizumab versus sunitinib, CLEAR	Grade ≥3 AEs 82.4% vs 71.8%⁴.	Review hypertension, diarrhea, fatigue, hepatic symptoms, and immune toxicity; dose holds are common management tools⁴.
Belzutifan versus everolimus, LITESPARK-005	Grade ≥3 any-cause AEs 61.8% vs 62.5%⁵.	Review anemia/hypoxia symptoms and urgent dyspnea; use regimen-specific monitoring⁵.

On-treatment monitoring

SOC/option regimen	Hallmark monitoring toxicity and available rate	Patient action / clinic response
Nivolumab plus ipilimumab	CheckMate 214: diarrhea 27%, grade 3–4 4%; hypothyroidism 16%, grade 3–4 <1%; increased lipase 16%, grade 3–4 10%; grade 3–4 treatment-related AEs 46% vs 63%¹.	Review bowel, lung, liver, skin, and endocrine symptoms before each infusion. Persistent diarrhea/abdominal pain, cough/dyspnea, jaundice, severe rash, or marked fatigue needs prompt contact; immune effects can persist and may require corticosteroids or hormone replacement¹.
Pembrolizumab plus axitinib	KEYNOTE-426: hypertension 44.5%, grade 3–5 22.1%; ALT increase 26.8%, grade 3–5 13.3%; diarrhea 54.3%, grade 3–5 9.1%; proteinuria 17.5%, grade 3–5 2.8%².	Check blood pressure and liver tests and review diarrhea, hand-foot/skin effects, proteinuria, and immune symptoms; severe headache/chest symptoms, jaundice, persistent diarrhea, or dyspnea needs prompt contact².
Nivolumab plus cabozantinib	CheckMate 9ER: diarrhea 63.8%, grade ≥3 6.9%; hypertension 34.7%, grade ≥3 12.5%; hand-foot syndrome 40.0%, grade ≥3 7.5%; ALT increase 28.1%, grade ≥3 5.3%³.	Monitor blood pressure, renal protein loss, diarrhea, hand-foot/skin changes, liver tests, thyroid function, and immune symptoms; severe diarrhea, bleeding, chest symptoms, jaundice, or dyspnea needs prompt contact³.
Pembrolizumab plus lenvatinib	CLEAR: hypertension 55.4%, grade ≥3 27.6%; diarrhea 61.4%, grade ≥3 9.7%; proteinuria 29.5%, grade ≥3 7.7%; hypothyroidism 47.2%, grade ≥3 1.4%⁴.	Monitor blood pressure, renal protein loss, diarrhea, hand-foot/skin changes, liver tests, thyroid function, and immune symptoms; severe diarrhea, bleeding, chest symptoms, jaundice, or dyspnea needs prompt contact⁴.
Belzutifan	LITESPARK-005 label treatment-arm rates (single-arm label rates for named events; no paired everolimus % in the retained label row): decreased hemoglobin 88%, grade 3–4 29%; hypoxia 15%, grade 3–4 10%⁵. LITESPARK-005 trial: grade ≥3 any-cause AEs 61.8% vs 62.5% with everolimus; discontinuation 5.9% vs 14.7% with everolimus⁵.	Check CBC and oxygen saturation; new fatigue, lightheadedness, palpitations, or shortness of breath should prompt contact and marked breathing difficulty needs urgent assessment⁵.

Epic phrase

#Metastatic renal cell carcinoma

Counseling: CheckMate 214 nivolumab/ipilimumab in IMDC intermediate/poor risk: 18-month OS about 75% vs 60% with sunitinib (OS HR 0.63 vs sunitinib). KEYNOTE-426 pembrolizumab/axitinib 12-month OS about 90% vs 78% with sunitinib (interim OS HR 0.53 vs sunitinib). CheckMate 9ER nivo/cabo PFS HR 0.51 vs sunitinib. No head-to-head comparison ranks doublets. Later belzutifan improved PFS vs everolimus after prior ICI and VEGFR therapy; OS was not statistically significant at reported analysis.
Counseling: Reviewed surveillance and de-escalation: imaging every 8–12 weeks during active response assessment on first-line therapy; after prolonged response, extend imaging intervals per EAU/NCCN when clinically appropriate. Complete nivo/ipi induction then maintenance; hold TKI/IO for toxicity; progression after ICI and VEGFR → belzutifan or trial; treatment breaks for doublets are not trial-established.
Monitoring: For IO/IO, review bowel, lung, liver, skin, and endocrine symptoms before each infusion. For IO/TKI, also check blood pressure, urine protein, liver tests, diarrhea, and hand-foot/skin effects. For belzutifan, check CBC and oxygen saturation. Promptly contact oncology for diarrhea/abdominal pain, cough/dyspnea, rash, jaundice, marked fatigue, hypertension symptoms, hand-foot/skin changes, or anemia/hypoxia symptoms. *** after-hours/urgent-assessment instructions reviewed.
Discussed histology and IMDC risk: * (clear cell / non-clear; favorable / intermediate / poor). Prior adjuvant pembrolizumab: *.
Disease extent: *. Prior nephrectomy / local therapy: *.
Discussed prognosis and goals.
Discussed treatment order: use IO/IO or an IO/TKI doublet first line according to risk, tumor burden, comorbidities, and priorities. After both ICI and antiangiogenic therapy, belzutifan is an evidence-based option; after IO/IO without prior VEGFR therapy, use a VEGFR-containing regimen before positioning belzutifan. Do not use the nivolumab/ipilimumab/cabozantinib triplet as default because it did not improve OS. ***
Discussed first-line options: IO/IO (nivolumab + ipilimumab, especially IMDC intermediate/poor) vs IO/TKI (pembrolizumab/axitinib, nivolumab/cabozantinib, pembrolizumab/lenvatinib) per risk, comorbidities, and need for early response. Triplet cabo + nivo/ipi improved PFS not OS in COSMIC-313 and is not default. He / she opts to proceed with *. Toxicities reviewed: * (irAEs; TKI: HTN, hand-foot, diarrhea, hepatic).
Labs / imaging: ***
Referrals: ***
Follow-up: ***

Edit markdown

Guideline references

Sources

Changelog

2026-09-22: Clarified response-assessment vs prolonged-response imaging schedule; expanded Biomarkers to five-column table (histology, IMDC, PD-L1, expression signatures, germline); mirrored extended-interval language in paired dotphrase.
2026-09-22: Renamed Upcoming trial results to Upcoming research; reframed for ongoing trials and field direction.
2026-09-22: Named everolimus as the LITESPARK-005 comparator in belzutifan monitoring rates; mirrored comparator-named efficacy counseling in the paired dotphrase.
2026-09-22: Added line-level source superscripts ([^n]) linked to numbered Sources.
2026-09-22: Added Surveillance and treatment de-escalation section; strengthened quantified benefit counseling in dotphrase.
2026-09-21: Added trial- and label-verified named monitoring rates for every listed IO/IO, IO/VEGFR, and belzutifan regimen.
2026-09-21: Added therapy sequencing and regimen-level on-treatment monitoring for IO/IO, each listed IO/VEGFR doublet, and belzutifan.
2026-09-21: Renamed the prospective-evidence section to Upcoming trial results.
2026-09-21: Removed Bottom line; added a compact Guidelines table and disease → setting page framing. No treatment recommendations or trial statistics changed.
2026-09-21: Weekly skim — no practice-changing updates since last review.
2026-09-14: expanded from stub; landscape table with both-arm outcomes for 1L doublets, COSMIC-313 no OS, LITESPARK-005, TiNivo-2, KEYNOTE-564 watch
2026-09-14: initial stub

Edit evidence markdown

Evidence page